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Abstract
Background: The dopamine-derived tetrahydroisoquinolines (TIQ) synthesized endogeneously
from aldehydes and catecholamines have shown to modulate neurotransmission, central
metabolism and motor activity. Converging evidence has implicated abnormalities of the dopamine
metabolism to the pathophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD).
Therefore, four TIQ derivatives involved in central dopamine metabolism (salsolinol, N-methyl-
salsolinol, norsalsolinol, N-methyl-norsalsolinol) have been analyzed for the first time in children
and adolescents with ADHD and healthy controls.
Methods: 42 children and adolescents with ADHD and 24 controls from three sites participated
in this pilot study. Free and bound amounts of salsolinol, N-methyl-salsolinol, norsalsolinol, N-
methyl-norsalsolinol have been analyzed in urine.
Results: In the ADHD group, free and total amounts of the four TIQ derivatives in urine were
significantly higher compared to urine levels of healthy controls. For N-methyl-salsolinolfree, most
of the ADHD patients were identified correctly with a sensitivity of 92.5% (specificity 94.4%).
Conclusion:  Urine levels of salsolinol, N-methyl-salsolinol, norsalsolinol and N-methyl-
norsalsolinol are elevated in children and adolescents with ADHD and point to a new perspective
on catecholaminergic dysfunction in ADHD. However, replication and extension of this pilot study
would progress this innovative and promising field.
Background
Attention-Deficit/Hyperactivity Disorder (ADHD) is a
common worldwide disorder characterized by inatten-
tion, impulsivity, and hyperactivity. Despite a large
amount of research its etiology still remains unclear. Actu-
ally, ADHD is regarded as a multifactorial disorder caused
by many interacting and/or additive risk factors [1]. There
is equivocal evidence from genetic, imaging and medica-
tion studies in humans as well as in animal models of
ADHD that dopamine and noradrenaline metabolism are
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affected [1,2]. Current models of ADHD propose a hypo-
functioning of e.g. three interacting dopamine systems
[3]: (1) the mesolimbic dopamine system primarily asso-
ciated with altered reinforcement of novel behavior and
deficient extinction of previously reinforced behavior, (2)
the mesocortical dopamine system associated with defi-
cient attention and poor behavioral organization and (3)
the nigrostriatal dopamine system impairing motor func-
tions and causing poor nondeclarative habit learning. But
the detailed mechanisms underlying these metabolic
impairments are still unknown [4]. Previous studies in
ADHD found only a limited relationship of plasma and
urine levels of dopamine metabolites to the activity of
central dopamine metabolism as well as small effects of
stimulant medication on urinary dopamine metabolites
[5]. Accordingly, studies on the levels of dopamine
metabolites in the cerebrospinal fluid have been per-
formed, but yielded also mixed results of limited value [6-
9].
In this context the dopamine-derived tetrahydroisoquino-
lines (TIQ) including salsolinol and norsalsolinol deriva-
tives are of high interest [10] because of their role as an
acute modulator of dopamine and noradrenaline neuro-
transmission (see [11] for a review). TIQ affect receptor
status, enzyme activity of the catecholamine biosynthesis
as well as mitochondrial metabolism. Furthermore, exog-
enously administered TIQ are known to produce changes
of motor activity in rodents [12-14].
TIQ are found at low concentrations in postmortem brain
[15], cerebrospinal fluid [16] and urine [17] of adults
without any neuropsychiatric disorder. In human brain
the highest concentration of the TIQ derivative salsolinol
and its metabolites have been detected in the basal ganglia
[18] – an area implicated in the etiology of ADHD [1].
Thus in ADHD deviations of TIQ levels might indicate dis-
turbances of dopamine and noradrenaline metabolism.
In the human brain, two TIQ derivatives salsolinol and
norsalsolinol are suggested to be synthesized from
dopamine by both a non-enzymatic formation via a
Pictet-Spengler reaction and an enzymatic synthesis via a
salsolinol synthase [19]; their N-methyl derivatives were
formed subsequently enzymatically by N-methyltrans-
ferase [20] (Fig. 1).
Because TIQ occur physiologically not only from their in
vivo formation but also from ingestion of various foods
[21,22], they seem to be worth to be investigated also in
the light of the ongoing debate concerning nutritional
influences on ADHD symptomatology [23,24].
Because there are still different hypotheses on hyper- and
hypodopamine deviances in central metabolism in
ADHD [25] and TIQ have never been examined in ADHD,
there is no directed hypothesis in our pilot study, i.e. it is
unclear if the four TIQ derivatives under investigation are
normal or enhanced versus reduced in the urine of chil-
dren and adolescents with ADHD compared to healthy
Physiological metabolism of TIQ derivatives Figure 1
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controls. Thus, the study also serves to generate a hypoth-
esis for further testing in larger samples.
Methods
Subjects
42 children and adolescents with ADHD (mean age 12.1,
SD 3.2 years) and 24 healthy controls (mean age 23.8, SD
17.0 years) from three sites (Departments of Child and
Adolescent Psychiatry of the Universities of Goettingen
and Wuerzburg, Department of Clinical Neurology of the
University of Vienna) were enrolled. All patients were
referred and fulfilled DSMIV-TR [26] criteria for ADHD.
18 patients were on stimulant medication at the day of
urine sampling. 16 patients suffered from one or more co-
existing psychiatric problems such as conduct disorder (n
= 13), learning disorders (n = 4), tic disorders (n = 2) and
others (n = 5).
Controls were recruited from hospital staff, their children
and a school class near Goettingen. All controls were
screened by an expert child and adolescent psychiatrist for
absence of psychiatric disorders and reported no medica-
tion before and during study participation.
Urine was collected over 12 hours starting at 7 p.m.. Study
participants were not allowed to consume food or bever-
ages rich in TIQ derivatives (cheese, chocolate, fresh and
dried banana, soya sauce, beer, Port and white wine) for
48 hours before urine samples were obtained [22].
The pilot study was approved by the ethics committees of
each participating sites. Informed consent was obtained
from the children and their parents. This study was con-
ducted in accordance with the Helsinki Declaration.
Urine analyses
The 12 h urine samples were collected in the presence of
50 mg semicarbazide and 50 mg Na2EDTA. All aliquot
samples collected were stored at -40°C and subsequently
measured by a two-step chromatography. Urine samples
were analyzed at least three times for all conditions, firstly
processed by affinity chromatography, and then TIQ
derivatives were quantified by high performance liquid
chromatography with electrochemical detection (HPLC/
ECD) as previously described [17,27]. Under our experi-
mental conditions, free and total concentrations of TIQ
compounds could be measured. As described earlier [28],
dihydroxylated TIQ derivatives are in part bound to sulfo-
or gluco-residues which can be deconjugated by incuba-
tion with arylsulfatases and β-glucuronidases. Since con-
jugated derivatives can not be detected directly, in our
study individual bound amounts were calculated by TIQ-
bound = TIQtotal-TIQfree.
Statistics
Statistical evaluations were conducted using the Statistical
Package for the Social Sciences (SPSS, version 12.0). Val-
ues were expressed in nM ± SEM as indicated [29]. We per-
formed analyses of variance (ANOVA) to compare the
concentrations of the TIQ derivatives among the groups
followed by analyses of covariance (ANCOVA) with age,
medication (yes/no), and co-existing psychiatric prob-
lems (yes/no) as covariates to control for these possible
confounders.
Results
In the ADHD group (n = 42), free and total concentrations
of all measured TIQ derivatives were increased in urine
samples compared to those of healthy controls (n = 24)
(ANOVA, Table 1). In contrast, of the conjugated TIQ
forms only the concentration of norsalsolinolbound was
significantly different between the groups.
Since the ADHD group and the healthy controls differed
in age (F = 18.99, df = 1,64, p < .001), and since the con-
trol group itself was heterogeneous in age (children: n =
13, mean age 10.5 SD 3.9 years; adults: n = 11, mean age
36.7 SD 11.3 years; F = 62.01, df = 1,22, p < .001), we sub-
sequently performed an ANCOVA with the covariate 'age'.
Additionally, because of differences in the ADHD group
in medication status (24 without versus 18 with) and co-
existing psychiatric problems (26 without versus 16 with)
two further covariates were included. There were signifi-
cant effects of the covariates 'medication status' (F =
11.53, df = 1, p < .001) and 'additional psychiatric diag-
noses' (F = 7.80, df = 1, p < .01) only for N-methyl-sal-
solinolfree. However, the same results as obtained using
ANOVA were found for all measured TIQfree derivatives
(ANCOVA, Table 1). In addition to the TIQfree derivatives,
also the concentrations of norsalsolinoltotal, norsalsolinol-
bound and N-methyl-norsalsolinoltotal remained increased
in ADHD.
To determine the predictive quality (ADHD yes/no) of
elevated TIQ levels (elevated yes/no) sensitivity and spe-
cificity were calculated. For the definition of an elevated
TIQ level an arbitrary limit was set by the mean of the free
concentration of the control group for each TIQ derivative
plus one SEM. Specificity is the proportion of true nega-
tives (no diagnosis of ADHD and no elevated TIQ level)
of all negative cases (no diagnosis of ADHD = all controls)
in the population; sensitivity is the proportion of true pos-
itives (diagnosis of ADHD and elevated TIQ level) of all
positive cases (all ADHD patients) in the population (sen-
sitivity/specificity (%): N-methyl-salsolinolfree: 92.5/94.4;
norsalsolinolfree: 87.8/80.0; N-methyl-norsalsolinolfree:
69.0/93.5; salsolinolfree: 55.5/95.2).Behavioral and Brain Functions 2007, 3:64 http://www.behavioralandbrainfunctions.com/content/3/1/64
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To exclude possibly confounding effects of age, medica-
tion and comorbidity not only statistically by including
covariates but also by strict in- and exclusion criteria of
both groups, we analyzed in a second step the data of 21
children and adolescents with ADHD compared to 19
healthy controls under the age of 18 years. There were no
differences in age (ADHD: n = 21, mean age 11.8 SD 3.5
years; controls: n = 12, mean age 9.5 SD 3.2 years; F =
3.50, df = 1,32, p > .05) and in the ADHD group there
were no patients with medication and comorbidity. The
group differences in TIQ levels remained as calculated by
the ANOVA in the whole sample for salsolinolfree (ADHD:
n = 16, mean = 5.64 SEM 2.02; controls: n = 12, mean =
0.11 SEM = 0.11; F = 5.56, df = 1,26; p < 0.05), salsolinol-
total (ADHD: n = 19, mean = 10.81 SEM 2.17 nmol; con-
trols: n = 12, mean = 0.22 SEM = 0.22 nmol; F = 14.78, df
= 1,29; p < .001), N-methyl-salsolinolfree (ADHD: n = 18,
mean = 66.28 SEM 8.27 nmol; controls: n = 10, mean =
10.50 SEM = 1.71 nmol; F = 24.54, df = 1,26; p < 0.001),
N-methyl-salsolinoltotal (ADHD: n = 20, mean = 116.52
SEM 13.03 nmol; controls: n = 11, mean = 46.09 SEM =
9.11 nmol; F = 13.85, df = 1,29; p < 0.001), norsal-
solinolfree (ADHD: n = 21, mean = 688.73 SEM 122.37
nmol; controls: n = 12, mean = 66.26 SEM = 14.64 nmol;
F = 14.52, df = 1,31; p < 0.001), norsalsolinoltotal (ADHD:
n = 21, mean = 1416.67 SEM 211.09 nmol; controls: n =
11, mean = 150.89 SEM = 28.09 nmol; F = 18.45, df =
1,30; p < 0.001), norsalsolinolbound (ADHD: n = 21, mean
= 727.93 SEM 102.37 nmol; controls: n = 10, mean =
94.70 SEM = 21.54 nmol; F = 17.72, df = 1,29; p < 0.001)
and N-Methyl-norsalsolinolfree (ADHD: n = 21, mean =
11.93 SEM 2.90 nmol; controls: n = 12, mean = 0.44 SEM
= 0.26 nmol; F = 8.79, df = 1,31; p < 0.01). Analogously,
the absence of group differences remained for N-methyl-
salsolinolbound (ADHD: n = 18, mean = 52.88 SEM 9.02
nmol; controls: n = 11, mean = 36.55 SEM = 9.31 nmol; F
= 1.43, df = 1,27; p = 0.243), N-Methyl-norsalsolinolbound
(ADHD: n = 18, mean = 30.52 SEM 13.46 nmol; controls:
n = 8, mean = 4.75 SEM = 1.68 nmol; F = 1.37, df = 1,24;
p = .25). For salsolinolbound (ADHD: n = 10, mean = 8.54
SEM 2.41 nmol; controls: n = 1, mean = 2.67) no group
comparison could be performed because in the control
group only for one child its concentration could be calcu-
lated successfully. For N-Methyl-norsalsolinoltotal the sig-
nificant difference between both groups including all
patients changed to a trend (ADHD: n = 21, mean = 38.10
SEM 13.88 nmol; controls: n = 12, mean = 4.81 SEM =
1.51 nmol; F = 3.23, df = 1,31; p = .08).
Discussion
Comparisons of urine concentrations of TIQ derivatives
between children and adolescents with ADHD and
healthy controls revealed higher concentrations of sal-
solinolfree, N-methyl-salsolinolfree, norsalsolinolfree, and
N-methyl-norsalsolinolfree in ADHD patients even when
considering three covariates (age, medication status, co-
Table 1: Urine levels of tetrahydroisoquinoline (TIQ) derivatives of children and adolescents with ADHD and healthy controls in nmol.
TIQ Derivative ADHD controls ANOVA ANCOVAa)
N concentration mean (SEM) N concentration mean (SEM) F F
Salsolinol
Free 36 8.44 (2.04) 24 0.06 (0.1) 11.17*** 5.87**
Total 38 19.34 (5.0) 24 2.79 (1.9) 6.57* 2.82ns
Boundcal 23 20.1 (7.2) 3 22.3 (11.0) 0.01ns 0.01ns
N-methyl-Salsolinol
Free 39 71.13 (8.6) 19 14.54 (4.0) 19.76*** 10.31**
Total 39 129.01 (17.8) 21 53.51 (6.9) 9.22** 3.12ns
Boundcal 37 59.0 (16.2) 19 32.0 (6.7) 1.61ns 0.23ns
Norsalsolinol
Free 41 553.30 (68.0) 24 121.50 (21.7) 22.64*** 25.73***
Total 42 1107.89 (123.7) 22 253.09 (53.37) 23.63*** 29.84***
Boundcal 39 599.4 (68.3) 17 195.1 (53.9) 13.58*** 20.78***
N-methyl-
Norsalsolinol
Free 42 9.06 (1.6) 24 0.94 (0.7) 77.07*** 12.28***
Total 42 33.76 (7.1) 24 10.64 (4.3) 5.38* 6.56*
Boundcal 38 27.3 (6.5) 13 17.9 (6.0) 0.63ns 1.88ns
a) covariates: age, medication (yes/no), co-existing psychiatric problems (yes/no); no effect of covariates except 'medication status' (F = 11.53; df = 
1; p < .001) and 'co-existing psychiatric problems' (F = 7.80; df = 1; p < .01) for N-methyl-salsolinolfree
* p < 0.5; ** p < 0.01;*** p < 0.001; ns = not significantBehavioral and Brain Functions 2007, 3:64 http://www.behavioralandbrainfunctions.com/content/3/1/64
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existing psychiatric problems) or when subjects with these
confounders were excluded. N-methyl-salsolinolfree
showed the highest sensitivity (92.5%) and specificity
(94.4%) of the four TIQ derivatives.
Although Moser et al [30] demonstrated a correlation
between salsolinol levels in urine and CSF and a time
course study of N-methyl-norsalsolinol in CSF indicated a
parallel decline of TIQ derivatives on both sides of the
blood-brain barrier [17,31] the evidence for a reliable cor-
relation between TIQ levels in urine and the central nerv-
ous system remains limited. However, analyses of urine
levels seem to be methodologically and ethically justified
as the first step to investigate TIQ in children with ADHD,
because in studies analyzing other dopamine metabolites
in the CSF, the lack of a control group [9] due to ethical
considerations [32] limited the significance of the find-
ings and they were not superior to the results of plasma or
urine analyses. Nevertheless, increased central dopamine
concentrations might cause increased concentrations of
salsolinol and norsalsolinol in urine resulting also in
increased urine concentrations of N-methyl-salsolinol
and N-methyl-norsalsolinol. This would support the
"hyperdopamine hypothesis" of ADHD which is in con-
trast to the majority of findings indicating hypodopamine
neurotransmission in ADHD [3,5] although some authors
combined both hypotheses to a comprehensive and more
complex model [25].
Interestingly, in the present study there is no hint for an
effect of the therapy with the psychostimulant methylphe-
nidate on TIQ levels, although the increase of the endog-
enously produced synaptic dopamine concentration
through inhibition of the dopamine transporter (DAT),
which takes up the dopamine into the presynaptic neu-
rons [33], might have led to higher concentrations of sal-
solinolfree and norsalsolinolfree.
In any case, concluding an exclusive relationship between
increased central dopamine metabolism and elevated
urine concentrations of TIQ derivatives might be an over-
simplified view because the found elevation of TIQ levels
in ADHD could result not only from primary central but
also from peripheral synthesis [17].
Because ingestion of TIQ influences their levels in urine
[21,22], participants of our study were not allowed to con-
sume food or beverages rich in TIQ derivatives for 48
hours before urine samples were obtained [22] and so var-
iations of exogenous TIQ or precursor intake might play a
minor role for the group differences found. Moreover, the
elevated levels of the non-conjugated TIQfree derivatives in
urine give evidence for endogenous synthesis rather than
oral ingestion, because ingested TIQfree derivatives will be
rapidly inactivated by gluco- or sulfo-conjugation pre-
venting elevated levels of non-conjugated TIQfree deriva-
tives in urine [28]. In addition, oral TIQ ingestion seems
unlikely to lead to a simultaneous increase of all four TIQ
derivatives in the ADHD group since on the contrary exog-
enous origin would lead to individual amount profiles of
the different TIQ derivatives. Nevertheless, nutritional
influences on ADHD symptomatology [23,24] can not be
completely ruled out because there may be an ADHD spe-
cific profile of changes in TIQ metabolism for each TIQ
derivative as an addition of the different TIQ sources.
Independently of considerations of causality, the sensitiv-
ity and specificity of TIQ urine levels, especially that for N-
methyl-salsolinol, which is much better than that of other
neurobiological procedures [1] needs confirmation and
differentiation by studies including the analyses of other
dopamine metabolites as well as including patients with
other disorders of dopamine dysfunction (e.g. tic disor-
ders, schizophrenia). Additionally, a further study with
larger sample size should differentiate between ADHD
subtypes. Since hyperactivity was found after injection of
TIQ in rodents [12-14], in ADHD there might be the
strongest correlation between the core symptom hyperac-
tivity and TIQ derivatives as well as the highest urine lev-
els in the predominantly hyperactive-impulsive subtype.
Conclusion
In conclusion, urine levels of salsolinol, N-methyl-salsoli-
nol, norsalsolinol and N-methyl-norsalsolinol are ele-
vated in children and adolescents with ADHD and point
to a new perspective on catecholaminergic dysfunction in
ADHD. Replication of the findings in a larger sample of
children and adolescents with ADHD focusing on sub-
types and including a control group of children with other
movement related catecholaminergic disorders would
progress this innovative and promising field of research.
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